The Role of Chemotherapy in Recurrent Malignant Gliomas: An Overview

References

• Walker M D, Alexander E, Hunt W E. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative trial. J Neurosurg 1978; 49: 333–343
   PubMed Web of Science ®Google Scholar
• Walker M D, Green S B, Byar D P. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 1980; 303: 1323–1329
   PubMed Web of Science ®Google Scholar
• Brant-Zawadzki M, Norman D. Magnetic Resonance Imaging of the Central Nervous System. Raven Press, New York 1987
   Google Scholar
• Doyle W K, Budinger T F, Valk P E. Differentation of cerebral radiation necrosis from tumor recurrence by (18 F) FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987; 11: 563–570
   PubMed Web of Science ®Google Scholar
• Black K L, Hawkins R A, Kim K T. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 1989; 71: 342–345
   PubMed Web of Science ®Google Scholar
• Karnofsky D A. Meaningful clinical classification of the therapeutic responses to anticancer drugs. Clin Pharmacol Ther 1961; 26: 709–712
   Google Scholar
• Levin V A, Wilson C B, Crafts D. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumor. J Neurosurg 1977; 47: 329–335
   PubMed Web of Science ®Google Scholar
• McDonald D R, Cascino T L, Clifford S. Response criteria for phase II studies ot supratentorial malignant glioma. I Clin Oncol 1990; 8: 1277–1280
   PubMed Web of Science ®Google Scholar
• Levin V A, Landhal H, Freeman-Dove M. The application of brain capillary permeability coefficient measurements to pathological conditions and the selections of agents which cross the blood brain barrier. J Pharmacokin Biopharmaceut 1976; 4: 499–503
   PubMedGoogle Scholar
• Weller R, Foy M, Cox S. The development and ultrastructure of the micro vasculature in malignant gliomas. Neuropathol Appl Neurobiol 1977; 3: 307–322
   Web of Science ®Google Scholar
• Yung W KA, Shapiro J R, Shapiro W R. Heterogeneous chemosensitivities of subpopulations of human glioma cells in colture. Cancer Res 1982; 42: 992–998
   PubMed Web of Science ®Google Scholar
• Osman Ali F. Drug resistance mechanisms: implications tor chemotherapy for primary brain tumors both inherent and acquired. 15th Imernatinal Cancer Congress, Hamburg, August 16–22, 1990; 25, abstract, 27, 02
   Google Scholar
• Schold S C, Brent T B, Von Hoff E. O6-Alkylguanine DNA alkiltransferase and sensitivity to procarbazine in human brain tumor xenografts. I Neurosurg 1989; 70: 573–577
   PubMed Web of Science ®Google Scholar
• Ali-Osman F, Schofield D. Cellular and molecular studies in brain and nervous system oncology. Curr Opin Oncol 1990; 2: 655–659
   PubMedGoogle Scholar
• Ali-Osman F, Stein D E, Renwick A. Glulathione content and glutathione-S-transferase expression in 1,3 bis (2-chloroethyl)-1-nitrosurea-resistant human: Malignant astrocytoma cell lines. Cancer Res 1990; 50: 6976–6980
   PubMed Web of Science ®Google Scholar
• Allalunis-Turner M J, Day R S, Me Kean J DS, et al. Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. J Neuro-Oncol 1991; 11: 157–160
   PubMed Web of Science ®Google Scholar
• Osman F A. Improved nitrosourea-based brain tumor therapy by pretherapeutic determination of tumor glutathione (GSH) and glutathione-S-transferase. 15th Internatinal Cancer Congress, Hamburg, August 16–22, 1990; 20, abstract, 27, 05
   Google Scholar
• Scheck A C, Beikman M K, Korn M C, et al. Regional analysis of genes potentially involved in resistance to BCNU in human malignant gliomas. Barrow Neurological Institute, SJHMC, Phoenix, AZ 85013. Proc Am Assoc Cancer Res 1991; 32: 358
   Google Scholar
• Wang A M, Elion G B, Friedman H S, et al. Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. Cancer Chemother Pharmacol 1991; 27: 278–282
   PubMed Web of Science ®Google Scholar
• Smith D C, Vixk N A, Trump D L, et al. Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. Cancer Chemother Pharmacol 1992; 30: 272–283
   PubMed Web of Science ®Google Scholar
• Albain K S, Swinnen L J, Ericksin L C, et al. Cisplatin preceded by concurrent cytarabine and hydroxyurea: A pilot study based on an in vitro model. Cancer Chemother Pharmacol 1990; 27: 33–39
   PubMed Web of Science ®Google Scholar
• Doz F, Berens M E, Spencer D R, et al. Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds. Cancer Chemother Pharmacol 1991; 28: 308–312
   PubMed Web of Science ®Google Scholar
• EORTC Brain Tumor Group. Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma: Final evaluation. Eur J Cancer 1978; 14: 851–856
   PubMed Web of Science ®Google Scholar
• Gregor A, Rampling R, Aapro M, et al. Phase II study of tauromustine in malignant glioma. Eur J Cancer 1992; 28, 1959–1962
   Google Scholar
• Frenay M, Giroux B, Khoury S, et al. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 1991; 27: 852–855
   PubMed Web of Science ®Google Scholar
• O'Reilly S M, Newlands E S, Glaser M G. Temozolamide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993; 29A: 940–942
   PubMed Web of Science ®Google Scholar
• Afra D. Vincristine therapy in malignant glioma recurrencies. Neurochirurgie 1973; 16: 189–198
   Google Scholar
• Djerassi I, Kim J S, Kassarov A. High dose methotrexate with citrovorum factor in astrocytoma. Proc Ann Meet Am Soc Clin Oncol 1988; 7: 314
   Google Scholar
• Rodriguez L A, Prados M, Silver P. Revaluation of procarbazine for the treatment of recurrent malignant central nervous system tumours. Cancer 1989; 64: 2420–2423
   PubMed Web of Science ®Google Scholar
• Spence A M, Berger M S, Livingston R B, et al. Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neuro-Oncol 1992; 12: 187–191
   PubMed Web of Science ®Google Scholar
• Kessinger A, Lemon H M, Foley J F. VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep 1979; 63: 511–512
   PubMedGoogle Scholar
• Tirelli U, D'Incalci M, Canetta M. Etoposide (VP-16–213) in malignant brain tumors: A phase II study. J Clin Oncol 1984; 2: 432–437
   PubMed Web of Science ®Google Scholar
• Poisson M, Pereon Y, Chiras J. Treatment of malignant supratentorial gliomas with carboplatin (CBDCA). J Neuro-Oncol 1991; 10: 139–144
   PubMed Web of Science ®Google Scholar
• Twelves C J, Ash C M, Miles D W. Activity and toxicity of car boplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 1991; 27: 481–483
   PubMed Web of Science ®Google Scholar
• Levin V A, Hoffman W F, Pischer T L. BCNU, 5-fluoruracil combination therapy for recurrent malignant brain tumors. Cancer Treat Rep 1978; 62: 2071–2076
   PubMedGoogle Scholar
• Levin V A, Phuphanich S, Liu H. Phase II study of combined carmustine, 5-fluoruracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. Cancer Treat Rep 1986; 70: 1271–1274
   PubMedGoogle Scholar
• Schold S C, Mahaley M S, Vick N A. Phase II AZQ based chemotherapy trials in patients with high grade supratentorial astrocytoma. J Clin Oncol 1987; 5: 464–470
   PubMed Web of Science ®Google Scholar
• Yung W K, Harris M I, Bruner J M. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neuro-Oncol 1989; 7: 237–240
   PubMed Web of Science ®Google Scholar
• Gutin P H, Wilson C B, Kumar A R. Phase II study of procarbazine, CCNU and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 1975; 35: 1398–1404
   PubMed Web of Science ®Google Scholar
• Eagan R T, Dinapoli R P, Hermann R C. Combination carmustine and dianhidrogalactitol in the treatment of primary brain tumors recurring after irradiation. Cancer Treat Rep 1982; 66: 1647–1651
   PubMedGoogle Scholar
• Levin V A, Edwards M S, Wright D C. Modified procarbazine CCNU and vincristine(PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 1980; 64: 237–241
   PubMedGoogle Scholar
• Boiardi A, Silvani A, Milanesi I, et al. Efficacy of “8 drugs in one day” combination in treatment of recurrent GBM patients. J Neuro-Oncol 1992; 12: 153–158
   PubMed Web of Science ®Google Scholar
• Rozental J M, Robins H I, Finlay J, et al. “Eight drugs in one day” chemotherapy in postirradiated adult patients with malignant gliomas. Med Pediatr Oncol 1989; 17: 471–476
   PubMedGoogle Scholar
• Levin V A, Prados M D. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 1992; 10: 766–771
   PubMed Web of Science ®Google Scholar
• Coyle T, Baptista J, Winfield J, et al. Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high grade glioma in adults: A phase II study. J Clin Oncol 1990; 8: 2014–2018
   PubMed Web of Science ®Google Scholar
• Buckner J C, Brown L D, Cascino T L. Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neuro-Oncol. 1990; 9: 249–254
   PubMed Web of Science ®Google Scholar
• Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 1992; 10: 1074–1079
   PubMed Web of Science ®Google Scholar
• Bullard D E, Gillespie G Y, Mahaley M S. Immunobiology of human gliomas. Semin Oncol 1986; 13: 94–99
   PubMed Web of Science ®Google Scholar
• Hitchcock E R, Morris C S. Mononuclear cell infiltration in central portions of human astrocytomas. J Neurosurg 1988; 68: 432–435
   PubMed Web of Science ®Google Scholar
• Miescher S, Whiteside T L, De Tribolet N. In situ characterization, clonogenic potential and anti-tumor cytolytic activity of lymphocytes infiltrating brain cancers. J Neurosurg 1988; 68: 438–444
   PubMed Web of Science ®Google Scholar
• De Tribolet N, Franck E, Mach J P. Monoclonal antibodies: Their application in the diagnosis and management of CNS tumours. Clin Neurosurg 1988; 34: 446–456
   PubMedGoogle Scholar
• Korosue K, Takeshita I, Mannoji H. Interferon effects on multiplication, cytoplasmic protein and GFAP content, and morphology in human glioma cells. J Neuro-Oncol 1983; 1: 69–73
   PubMedGoogle Scholar
• Mihara Y, Kuratsu J, Takaki S, et al. Distribution of mouse interferon-b in normal and brain tumor-bearing mice. Acta Neurochir 1991; 109: 46–49
   PubMed Web of Science ®Google Scholar
• Yung W KA, Prados M, Levin V A. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I/II study. J Clin Oncol 1991; 9, 1945–1950
   Web of Science ®Google Scholar
• Nagai M, Arai T. Clinical effect of interferon in malignant brain tumors. Neurosurg Rev 1984; 7: 55–64
   PubMedGoogle Scholar
• von Wild K RH, Knocke T H. The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma: A phase II study. Neurosurg Rev 1991; 14: 203–207
   PubMed Web of Science ®Google Scholar
• Duff T A, Borden E, Bay J. Phase II trial of interferon beta for treatment of recurrent glioblastoma multiforme. J Neurosurg 1986; 64: 408–413
   PubMed Web of Science ®Google Scholar
• Mahaley M S, Urso M B, Whaley R A. Immunobiology of primary imracranial tumors. X. Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 1985; 63: 719–725
   PubMed Web of Science ®Google Scholar
• Hirakawa K, Ueda S, Nakagawa Y. Effect of human leukocyte interferon on malignant brain tumors. Cancer 1983; 51, 1976–1981
   PubMed Web of Science ®Google Scholar
• Buckner J C, Brown L D, Cascino T L. Recombinant alpha-interferon and BCNU in recurrent gliomas. J Biol Response Mod 1989; 8: 332–333
   Google Scholar
• Brandes A, Rigon A, Zampieri P, et al. Phase II trial with BCNU plus alfa 2 B interferon (IFN) in patients (PTS) with recurrent high grade gliomas. 4th Intern Congress on Anti-cancer Chemotherapy, Paris, Feb 2–3, abstract no. 235
   Google Scholar
• EORTC Brain Tumor Cooperative Group: Effect of AZQ(1,4-Cyclohexadiene-1, 4-diacarbamic-acid-2, 5-bisl-aziridynyl-d3,6-dioxodiethylester) in recurring supratentorial malignant brain gliomas: A phase II study. Eur J Clin Oncol 1985; 21: 143–146
   PubMedGoogle Scholar
• Feun L G, Yung W K, Leavens M E. A phase II trial of 2,5-diaziridynyl-3–6-bis(carbohethoxy-amino)1, 4-benzoquinone) AZQ: NSC 182986 in recurrent primary brain tumors. J Neuro-Oncol 1984; 2: 13–17
   PubMed Web of Science ®Google Scholar
• Broder L E, Carter S K. Clinical brochure BCNU (NSC-409962). Bethesda, MD 1970
   Google Scholar
• Wilson C B, Boldrey E B, Enot K J. 1,3-Bis (2-chloroelhyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 1970; 54: 273–281
   PubMedGoogle Scholar
• Yung W K, Mechtler L, Gleason M J. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991; 9: 860–864
   PubMed Web of Science ®Google Scholar
• Hansen H H, Muggia F M. Treatment of malignant brain tumors with nitrosoureas. Cancer Chemother Rep 1971; 55: 99–100
   PubMedGoogle Scholar
• Hoogstraten B, Gottlieb J A, Caoili E. CCNU(l-(2-chloroelhyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer: Phase II study. Cancer 1973; 32: 38–43
   PubMed Web of Science ®Google Scholar
• Taylor S A, Crowley J, Townsend J. Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies. J Neuro-Oncol 1993; 15: 181–184
   PubMed Web of Science ®Google Scholar
• Cascino T L, Brown L D, Morton F M. Evaluation of fludarabine phosphate in patients with recurrent glioma. Am J Clin Oncd 1988; 11: 586–588
   PubMed Web of Science ®Google Scholar
• Georges P, Przedboski S, Brotchi J. Effect of Hecnu in malignant supralentorial gliomas: A phase II study. J Neuro-Oncol 1988; 6: 211–217
   PubMed Web of Science ®Google Scholar
• Feun L J, Savaraj N, Landy H. Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. J Neuro-Oncol 1990; 9: 159–163
   PubMed Web of Science ®Google Scholar
• Jaekle K A, Mittleman A, Hill F H. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. J Clin Oncol 1990; 8: 1408–1411
   PubMed Web of Science ®Google Scholar
• Elliott T E, Buckner J C, Cascino T L. Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neuro-Oncol 1991; 10: 27–30
   PubMed Web of Science ®Google Scholar
• Carapella C M, Iandolo B, Chiaie Dalle S. Lonidamine in primary brain tumors. Oncology 1984; 41(Suppl 1)82–85
   PubMedGoogle Scholar
• Young R C, Walker M D, Canellos G P. Initial clinical trials with methyl-CCNU l-(2-chloroethyl)-3–(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU). Cancer 1973; 31: 1164–1169
   PubMed Web of Science ®Google Scholar
• Chamberlain M C, Prados M D, Silver P A. A phase II trial of oral melphalan in recurrent primary brain tumors. Am J Clin Oncol 1988; 11(1)52–54
   PubMed Web of Science ®Google Scholar
• Stewart D J, Hugenholz H, DaSilva V F. Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults. J Neuro-oncol 1992; 13: 183–188
   PubMed Web of Science ®Google Scholar
• Stewart D J, Hugenholz H, Russel N. Phase II study of novantrone (mitoxantrone hydrocloride) in adults with III-IV astrocytomas. Biology of Brain Tumor, M D Walker, D GT Thomas. Marlinus Nijhoff Publishers, Boston 1986; 411–413
   Google Scholar
• Levin V A, Resser K J, McGrath L. PCNU treatment for recurrent malignant gliomas. Cancer Treat Rep 1984; 68: 969–973
   PubMedGoogle Scholar
• Gerosa M A, Di Stefano E, Olivi A. VM-26 monochemotherapy trial in the treatment recurrent supratentorial gliomas: Preliminary report. Surg Neurol 1981; 15: 128–131
   PubMed Web of Science ®Google Scholar
• Alavi J B, Weiler C B, Bruno L A. Phase II evaluation of vindesine in the treatment of malignant glioma. Cancer Treat Rep 1984; 68: 807–808
   PubMedGoogle Scholar
• Ameri A, Poisson M, Chen Q M, et al. Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: A phase II study. J Neuro-Oncol 1993; 17: 43–46
   PubMed Web of Science ®Google Scholar